This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
Agios Pharmaceuticals, the company behind the only two IDH-targeted drugs on the market and a brain-penetrant IDH inhibitor in late-stage testing for glioma, announced plans to sell its oncology business to Servier for up to $2 billion plus royalties.
- ©2021 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
March 2021
Volume 11, Issue 3
Volume 11, Issue 3
Agios Exits Oncology
Jump to section
Advertisement